These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30755630)

  • 1. Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin.
    Matsuoka T; Yoshida Y; Aisu N; Yamada T; Mogi A; Komono A; Sakamoto R; Kojima D; Yoshimatsu G; Kiyomi F; Kodama S; Hasegawa S
    Sci Rep; 2019 Feb; 9(1):1819. PubMed ID: 30755630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration.
    Yoshida Y; Mogi A; Aisu N; Yamada T; Matsuoka T; Kojima D; Mera T; Koganemaru T; Kiyomi F; Noda K; Takamatsu Y; Tamura K; Yamashita Y; Hasegawa S
    Springerplus; 2016; 5(1):1872. PubMed ID: 27822446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205).
    Suwa Y; Watanabe J; Ota M; Suzuki S; Suwa H; Watanabe K; Saito S; Nagamine K; Momiyama M; Ishibe A; Saigusa Y; Yamanaka T; Endo I
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):419-424. PubMed ID: 30523381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain.
    Kawazoe H; Sumikawa S; Nakauchi K; Yakushijin Y; Yamamoto Y; Watanabe Y; Tanaka A; Araki H
    Int J Clin Pharm; 2017 Dec; 39(6):1291-1297. PubMed ID: 29027645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Search for Factors Related to Vascular Pain Expression upon Administration of Oxaliplatin into a Peripheral Vein].
    Takagi A; Yonemoto N; Aoyama Y; Touma Y; Kajiwara M; Watanabe K; Miyazaki Y; Koinuma M
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):887-9. PubMed ID: 26197757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain.
    Nagao S; Furihata M; Fukagawa K; Furihata T; Matsuhashi Y; Wada T
    J Infect Chemother; 2017 Jul; 23(7):493-497. PubMed ID: 28285948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin infusion-related venous pain: prevention by simultaneous intravenous fluids.
    van Ravensteijn S; van Merrienboer B; van Asten S; Pruijt J; Hilbink M; Tol J
    BMJ Support Palliat Care; 2021 Jun; 11(2):226-229. PubMed ID: 32451327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy.
    Yoshida Y; Mogi A; Yamada T; Aisu N; Matsuoka T; Kojima D; Tanimura S; Koganemaru T; Oda M; Fukuda M; Kiyomi F; Noda K; Hirata K; Yamashita Y
    Springerplus; 2015; 4():822. PubMed ID: 26753110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy.
    Yoshida Y; Satoh A; Yamada T; Aisu N; Matsuoka T; Koganemaru T; Kajitani R; Munechika T; Matsumoto Y; Nagano H; Komono A; Sakamoto R; Morimoto M; Arima H; Hasegawa S
    Sci Rep; 2019 Dec; 9(1):20361. PubMed ID: 31889149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
    Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods.
    Suga Y; Ikeda N; Maeda M; Staub AY; Shimada T; Yonezawa M; Kitade H; Katsura H; Okada M; Ishizaki J; Sai Y; Matsushita R
    J Pharm Health Care Sci; 2018; 4():18. PubMed ID: 30094053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
    Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin.
    Watanabe D; Fujii H; Yamada Y; Iihara H; Ishihara T; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
    Anticancer Res; 2020 Jan; 40(1):299-304. PubMed ID: 31892580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk Factors for Oxaliplatin-Induced Phlebitis and Venous Pain, and Evaluation of the Preventive Effect of Preheating with a Hot Compress for Administration of Oxaliplatin].
    Nakauchi K; Kawazoe H; Miyajima R; Waizumi C; Rokkaku Y; Tsuneoka K; Higuchi N; Fujiwara M; Kojima Y; Yakushijin Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(11):1397-400. PubMed ID: 26602398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer.
    Nagata T; Fukuda KI; Tamai M; Taniguchi A; Kamiya H; Kambe K; Kamada Y; Iwata G; Yamaoka N
    Anticancer Res; 2019 Mar; 39(3):1347-1353. PubMed ID: 30842168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO).
    Hata T; Honda M; Kobayashi M; Toyokawa A; Tsuda M; Tokunaga Y; Takase K; Miyake M; Morita S; Nagata N; Sakamoto J; Gosho M; Mishima H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1209-15. PubMed ID: 26560483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.